Final Debarment Order: Ricardo Andres Acuna
FDA issued a final debarment order against Ricardo Andres Acuna, prohibiting him from providing services in any capacity to a drug product applicant or holder of an approved or pending application.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 31, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Low urgency. Pharmaceutical companies, especially those with approved or pending drug applications, that might employ or contract with Ricardo Andres Acuna. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Immediate effect; no specific deadline provided.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
Ricardo Andres Acuna is now debarred by the FDA, meaning he cannot provide services in any capacity to a drug product applicant or holder of an approved or pending application.
Who it affects
Pharmaceutical companies, especially those with approved or pending drug applications, that might employ or contract with Ricardo Andres Acuna.
What you must do
Review current and future relationships to ensure Ricardo Andres Acuna is not providing services to your company in any capacity related to drug applications.
Deadline
Immediate effect; no specific deadline provided.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- Novo Nordisk’s Bloomington Plant Receives FDA OAI Designation Following Contamination and Compliance Issues - pharmaceuticalcommerce.com
- Uyghur Forced Labor Prevention Act Entity List
- Final Debarment Order: Angela Anatilde Baquero
- Guidance: Biosimilar and Interchangeable Biosimilar Products: Considerations for Container Closure Systems and Device Constituent Parts
- Guidance: Assessing Adhesion with Transdermal and Topical Delivery Systems for Abbreviated New Drug Applications